MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function
详细信息 查看全文
- 作者：Asfar S. Azmi ; Amro Aboukameel ; Sanjeev Banerjee ; Zhiwei Wang ; Momin Mohammad ; Jack Wu ; Shaomeng Wang ; Dajun Yang ; Philip A. Philip ; Fazlul H. Sarkar ; Ramzi M. Mohammad
- 关键词：MDM2 and p53 ; Small molecule inhibitors ; Cisplatin ; Apoptosis ; Pancreatic cancer
- 刊名：European Journal of Cancer
- 出版年：2010
- 出版时间：April 2010
- 年：2010
- 卷：46
- 期：6
- 页码：1122-1131
- 全文大小：3773 K
文摘
Small molecule inhibitors (SMIs) of murine double minute 2 (MDM2) are known to restore the apoptotic and cell cycle regulatory functions of p53 by disrupting the MDM2–p53 interaction. In principle, these SMIs are not effective against tumours with mutation in the tumour suppressor p53 (mut-p53), which is known to be present in approximately 50 % of all cancers. In this study we are reporting, for the first time, that MI-319 in combination with cisplatin induced cell growth inhibition and apoptosis in pancreatic cancer (PC) cells irrespective of their p53 mutational status. MI-319–cisplatin combination synergistically suppressed cell growth (MTT Combination Index [CI] < 1) and colony formation (clonogenic assay) and induced apoptosis. Western blot analysis and siRNA silencing studies in mutant as well as p53 null cells highlighted a mechanism involving p73 which is also known to be under the regulation of MDM2, and unlike p53, it is rarely mutated in PC. Down-regulating MDM2 using siRNA enhanced p73 reactivation and increased cell death. Further, the combination effectively reduced tumour growth in both wt-p53 and mut-p53 tumour xenograft models (50 % Capan-2 animals were tumour free). Consistent with our in vitro results, remnant tumour tissue analysis showed up-regulation of p73 and the cell cycle regulator p21. In conclusion, this study highlights a new role of MDM2 inhibitors in combination with cisplatin, and thus warrants further clinical investigation in human pancreatic tumours containing both wt-p53 and mut-p53.